PEA: an endogenous relative of CBD, the PPAR-alpha mechanism and mast cells (dosage)

Palmitoylethanolamide, or PEA for short, is a substance that the body produces, especially in inflamed areas. It is sometimes referred to as the endogenous relative of CBD because it belongs to the same chemical family as anandamide, although it acts through a different receptor. In chronic pain, it has been the subject of two independent meta-analyses and a safety review, making it one of the few supplements that can be discussed with data from randomized studies rather than just theory. Below you will find a description of the mechanism, a summary of what has actually been studied and on what sample, and what is still unknown about the long-term safety of PEA. Separately, we explain the source of the buzz around the ultramicronized form and why this article does not provide dosages for self-administration.

KEY INFORMATION
• PEA acts through the nuclear receptor PPAR-alpha. In the study by Lo Verme, it activated it at a half-maximal concentration of 3.1 micromoles, and its anti-inflammatory effect disappeared in mice lacking this receptor (Lo Verme i in., Molecular Pharmacology, 2005).
• The meta-analysis by Artukoglu included 10 randomized studies, 786 patients taking PEA, and 512 people in control groups; PEA significantly reduced pain more than inactive control (Artukoglu i in., Pain Physician, 2017).
• The analysis of pooled data from 12 studies showed a decrease in pain intensity of 1.04 points over two weeks compared to 0.20 points in control groups (Paladini i in., Pain Physician, 2016).
• Safety data extend to therapies lasting up to 49 days. For treatments longer than 60 days, the number of patients studied is too small to rule out rarer adverse effects (Gabrielsson i in., British Journal of Clinical Pharmacology, 2016).
• This article does not provide dosages for self-administration. Decide on supplementation with your doctor, especially when taking medications simultaneously.

What is PEA and why is it sometimes referred to as a relative of CBD?

PEA is an endogenous lipid from the N-acylethanolamines group, which is the same chemical family as anandamide. The body produces it on its own, and production increases in response to tissue damage and inflammation. Its relation to CBD is therefore chemical and functional, not literal: CBD comes from a plant, while PEA is produced in the human body.

However, calling PEA natural CBD is misleading, as the mechanisms of both compounds diverge. PEA does not bind to cannabinoid receptors CB1 and CB2 with high affinity. Its main molecular target is the nuclear receptor PPAR-alpha, a transcription factor that regulates the expression of genes related to inflammation and lipid metabolism. This is a completely different pathway than that taken by non-steroidal anti-inflammatory drugs, which block cyclooxygenase enzymes.

The practical consequence of this difference is that PEA is considered a supplement rather than a substitute for plant cannabinoids. A broader discussion of this entire group of compounds, along with the related OEA, can be found in a separate text about endocannabinoid system and compounds outside of anandamide.

How does PEA work at the cellular level?

The best-documented element of this mechanism is the dependence on PPAR-alpha. Lo Verme and colleagues demonstrated that PEA selectively activates this receptor under laboratory conditions, achieving a half-maximal concentration of 3.1 micromoles, and increases the expression of its messenger RNA when applied to the skin of mice. However, the decisive result comes from two animal models of inflammation: PEA alleviated paw swelling induced by carrageenan and ear swelling induced by phorbol ester in healthy mice, but did not work in mice lacking the PPAR-alpha gene (Lo Verme i in., Molecular Pharmacology, 2005).

This second result is stronger than merely stating a correlation, as it shows that without the receptor, the effect disappears. Other known substances that stimulate PPAR-alpha behaved similarly, further indicating a common pathway of action. It is worth noting that these are studies on animals and in cell cultures, not in humans.

Mast cells appear in descriptions of PEA because they are one of the first links in the inflammatory response and release mediators that sustain pain. Meta-analyses of PEA efficacy refer to the inhibition of their activation and the impact on glial cells as a proposed explanation for the observed analgesic effect. Thus, this is a mechanistic hypothesis consistent with clinical data, not separately proven in humans. A separate text discusses another pathway of pain modulation, leading through the TRPV1 receptor and capsaicin.

What exactly has been studied and on what sample?

Instead of a dosage table that would suggest a ready recommendation, below is a summary of the studies themselves: who conducted them, what type they were, how many papers and people they included, and what the results were. This allows for an assessment of the strength of evidence before anyone starts talking about use.

Note the last line. The advantage of the ultramicronized form was demonstrated in rats that were administered the isotopically labeled compound orally (Petrosino i in., Frontiers in Pharmacology, 2018). In humans, the situation is different: the Gabrielsson review states that no direct comparisons of the micronized form with the regular one were conducted in patients, so there is currently no evidence of superiority for either. Therefore, the label declaration refers to the manufacturing technology, not to clinically confirmed superiority.

What do meta-analyses of PEA efficacy show?

Two independent meta-analyses provide a consistent direction of results. Artukoglu and colleagues identified 10 randomized studies involving 786 patients taking PEA and 512 individuals in control groups; eight studies with inactive control were included in the proper analysis. PEA was associated with a significantly greater reduction in pain intensity on the visual analog scale compared to control, with a weighted mean difference of 2.03 points and a confidence interval from 1.19 to 2.87 (Artukoglu i in., Pain Physician, 2017).

Paladini and colleagues combined raw data from 12 studies, including three double-blind trials against placebo, two open-label against standard therapy, and seven open-label without a comparative group. Pain intensity decreased by 1.04 points every two weeks, while in control groups it decreased by 0.20 points. On day 60, pain at level 3 or lower was reported in 81% of individuals taking PEA compared to 40.9% in the control, and the effect was independent of the patients' age or gender (Paladini i in., Pain Physician, 2016).

Both studies also indicate limitations that should not be overlooked. The number of studies is small, they concern different causes of pain, and the quality of some is assessed as poor, especially regarding the reporting of adverse events. In Paladini's analysis, seven out of twelve studies were open-label without a comparative group, which weakens the conclusions. Therefore, a cautious conclusion is: the signal of efficacy is repeatable, but the evidence base remains narrow.

Can PEA be combined with CBD?

There is practically no clinical research on such a combination, and that is the most honest answer. Both compounds are described as acting through different, partially overlapping pathways: PEA mainly through PPAR-alpha, CBD through a broader set of molecular targets. However, just because the mechanisms complement each other does not mean that the clinical effect adds up. No one has measured the presumed synergy in humans.

A separate issue is the safety of CBD itself in such a combination. EFSA states that the safety of cannabidiol cannot be established in individuals under 25 years of age, in pregnant and breastfeeding women, and in individuals taking medications, and the provisional safe dose derived in this assessment is 0.0275 mg per kilogram of body weight per day, which is about 2 mg for a person weighing 70 kg (EFSA, EFSA Journal, 2026). Combining two preparations without a doctor's knowledge is therefore a decision fraught with risk, which no one has assessed for you.

This is especially relevant for individuals who turn to PEA precisely because non-steroidal anti-inflammatory drugs are contraindicated for them. The contraindication usually arises from a comorbid condition or from medications being taken, which are exactly the circumstances in which safety assessment becomes difficult. The context of inflammatory diseases is discussed more broadly in the text about CBD a chorobach autoimmunologicznych.

Frequently Asked Questions

What is PEA and why is it called a relative of CBD?

PEA is palmitoylethanolamide, an endogenous lipid from the N-acylethanolamines family, which also includes anandamide. The body produces it in response to tissue damage. Its relation to CBD concerns the chemical class and area of action, not the mechanism, as PEA primarily acts through the PPAR-alpha receptor, not through cannabinoid receptors.

Is the effectiveness of PEA confirmed by research?

Two meta-analyses provide a consistent direction of results in chronic and neuropathic pain. However, the foundation is narrow: 10 randomized studies by Artukoglu and 12 papers in Paladini's pooled data analysis, of which seven were open-label studies without a control group. The authors of both papers call for further, better-designed studies.

What is known about the safety of long-term use of PEA?

Gabrielsson's review includes therapies lasting up to 49 days, and for such a period, it finds no evidence of serious adverse effects occurring more frequently than in one in two hundred people. For treatments longer than 60 days, the number of patients studied is too small to rule out rarer adverse effects.

Does PEA interact with medications?

Reliable data on PEA interactions with medications are scarce, so the absence of documented interactions is not the same as proof of their non-existence. If you are taking prescription medications, especially anti-inflammatory, anticoagulant, or steroid drugs, discuss the decision to supplement with your doctor or pharmacist before starting.

What is the difference between ultramicronized PEA and regular PEA?

Ultramicronization reduces particle size, which is intended to improve the absorption of substances that are poorly soluble in water. Higher concentrations in plasma for this form have been shown in rats. In humans, direct comparisons of both forms have not been conducted, so there is currently no evidence of clinical superiority for either.

You will find these types of products in the category supplements.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use hemp or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Opublikowano: 2026-07-10 · Aktualizacja: 2026-08-11